The weekly litigation news digest is live. Subscribe now

IP Verse

Therapeutic Compositions Containing Macitentan - EP3300729

The patent EP3300729 was granted to Actelion Pharmaceuticals on Oct 9, 2019. The application was originally filed on Aug 12, 2009 under application number EP17191033A. The patent is currently recorded with a legal status of "Revoked".

EP3300729

ACTELION PHARMACEUTICALS
Application Number
EP17191033A
Filing Date
Aug 12, 2009
Status
Revoked
Oct 14, 2024
Publication Date
Oct 9, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
GENERICS UKJul 9, 2020HGFADMISSIBLE
STADA ARZNEIMITTELJul 9, 2020HAMM & WITTKOPPADMISSIBLE
AERAJul 6, 2020AERAADMISSIBLE

Patent Citations (13) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS4474802
DESCRIPTIONUS4539333
DESCRIPTIONUS4683330
DESCRIPTIONUS4692464
DESCRIPTIONUS7205302
DESCRIPTIONWO02053557
DESCRIPTIONWO2004017993
OPPOSITIONWO02053557
OPPOSITIONWO2008026156
SEARCHUS7205302
SEARCHWO02053557
SEARCHWO2004017993
SEARCHWO2005030187

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents